Company record · ABT · Pharmaceutical Preparations
Abbott Laboratories
The principal financial officer who signed Abbott Laboratories's latest annual report, the 10-K filed February 20, 2026, is Philip P. Boudreau.
The record holds the CFO signature on Abbott Laboratories's 10-K filed February 20, 2026 and no Form 8-K CFO change.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Philip P. Boudreau |
| Title as printed | Executive Vice President, Finance and Chief Financial Officer (principal financial officer) |
| Basis | Verified February 20, 2026: the 10-K signature block (sec.gov) |
Seat timeline
1Every verified record for this seat, newest first, dated as the filing states it.
2026-02-2010-K signature
Philip P. Boudreau signed the annual report as Executive Vice President, Finance and Chief Financial Officer (principal financial officer)
10-K filed February 20, 2026 · sec.gov
“/s/ PHILIP P. BOUDREAU Robert B. Ford Philip P. Boudreau Chairman of the Board and Chief Executive Officer, and Director of Abbott Laboratories (principal executive officer) Executive Vice President, Finance and Chief Financial Officer (principal financial officer)”
Company
| Ticker | ABT |
|---|---|
| SEC CIK | 0000001800 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | The DEF 14A filed 2026-03-13 also names Philip P. Boudreau alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-04-27, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Cadrenal Therapeutics, Inc.CVKD
Interim CFO: John P. Sharp · effective June 25, 2026
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
BeyondSpring Inc.BYSI
CFO: Na Li · effective July 1, 2026
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.